Pfizer Inc. (NYSE: PFE) achieved strong financial results for the second quarter, fueled by continuous cost-cutting measures and outstanding commercial execution across important products. The company increased its full-year adjusted diluted EPS outlook to $2.90–3.10 and announced operating-based sales of $14.7 billion, up 10% from the previous year.
Key Financial Highlights
- $14.7 billion in revenue, a 10% increase in operations compared to Q2 2024
- Diluted EPS reported: $0.51
- $0.78 is the adjusted diluted EPS.
- Reaffirmed revenue guidance for 2025 is $61.0–64.0 billion.
- Adjusted EPS Guidance for 2025: increased by $0.10 to $2.90–3.10 (absorbing the impact of the 3SBio licensing fee of about $0.20).
- By the end of 2027, the net cost savings target is expected to reach $7.2 billion.
Read More: FDA approves Pfizer’s pneumococcal vaccines for children and infants
Product Performance
- Vyndaqel family: +21%, indicating increased patient diagnosis and robust U.S. uptake
- Comirnaty (COVID-19 vaccine): increased by 95% due to overseas deliveries and a larger U.S. market share
- Paxlovid (COVID-19 antiviral): +71% as a result of favorable price transition and rebate changes in the United States
- Padcev (urothelial cancer): +38% thanks to a shift in distribution and a larger market share
- Eliquis (anticoagulant): +6%, as price reductions in the US were offset by increased demand worldwide.
- Abrysvo (RSV vaccine): +155%, led by additional international launches and maternal indication demand in the U.S.
- Lorbrena (ALK+ lung cancer): +48%, indicating US, Chinese, and a few other markets’ first-line uptake.
Read More: Johnson & Johnson Beats Q2 Estimates, Raises 2025 Outlook on Strong Sales Growth
Operational Efficiency and Cost Management
- Because of a positive 2024 royalty adjustment, the cost of sales increased by 0.9 percentage points.
- Operationally, SI&A expenses decreased by 8% as a result of optimized marketing expenditures.
- Due to pipeline priority and reduced compensation costs, R&D expenses have decreased by 8% operationally.
Pfizer had another strong quarter of focused execution and we’re pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company for the future and we’re confident in our ability to create further value for patients and our shareholders.
Dr. Albert Bourla
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
